Therapeutic Interventions For Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL) (TINALL)
Acute Lymphoblastic Leukemia
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Supportive Care
|Official Title:||Therapeutic Interventions For Peripheral Neuropathy/Neuropathic Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL) On Total XVI Protocol|
- Daily total dose of oral morphine (mg/kg/day). [ Time Frame: Daily beginning day 1 for a maximum of 21 days. ] [ Designated as safety issue: No ]A quantity measured by pill count and/or adherence interview
- Pain scores right now [ Time Frame: Daily beginning day 1 through a maximum of 21 days. ] [ Designated as safety issue: No ]A score ranging from 0 to 10, measured by age appropriate validated pain scale
- Pain score during the previous 24 hours [ Time Frame: Daily beginning day 1 through a maximum of 21 days ] [ Designated as safety issue: No ]A score ranging from 0 to 10, measured by age appropriate validated pain scale
|Study Start Date:||January 2012|
|Estimated Study Completion Date:||January 2017|
|Estimated Primary Completion Date:||January 2017 (Final data collection date for primary outcome measure)|
Active Comparator: Gabapentin
Active treatment arm.
Participants randomized to the active treatment arm will receive gabapentin 20mg/kg/day PO divided into 3 doses and rounded to the nearest 100 mg for capsules and 10 mg for liquid preparation.
Other Name: Treatment Arm
Placebo Comparator: Placebo
Participants randomized to the placebo treatment arm will receive look-alike capsules or liquid in a respective capsule size or liquid measure equivalent to the active treatment arm, but which contain no active treatment.
Other Name: Placebo Arm
Patients with ALL on Total XVI who experience NP/PN after specific doses of vincristine are eligible to enroll in the study as soon as the diagnosis of NP/PN related to VCR is established. The qualifying doses of vincristine have been selected because they fall in the schedule of weekly vincristine doses as per Total XVI, and 2 additional weekly vincristine doses are anticipated according to the protocol. Participants will be randomized to receive gabapentin or placebo upon enrollment. Morphine will be available to both groups as needed for pain at any time on the study. At the time of enrollment, and daily thereafter until completion of the study drug, data will be collected for pain assessment, and the daily dose of oral morphine used will be collected. Data regarding the pain type, quality, and location, as well as treatments used to manage pain will be assessed on a daily basis for the diagnostic event and for the period following the next two administrations of VCR treated with the study drug.
Primary Objective: To assess the analgesic efficacy of gabapentin in controlling VCR-related NP/PN in participants with ALL, by comparing the morphine daily dose (mg/kg/day) used to control NP/PN as a primary or a rescue regimen in the gabapentin vs. placebo groups.
Secondary Objective: To compare the pain scores in the gabapentin and placebo groups as recorded by pain score right now and pain score average for previous 24 hours.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01506453
|Contact: Doralina Anghelescu, MDfirstname.lastname@example.org|
|United States, Tennessee|
|St. Jude Children's Research Hospital||Recruiting|
|Memphis, Tennessee, United States, 38105|
|Contact: Doralina Anghelescu, MD 866-278-5833 email@example.com|
|Principal Investigator: Doralina Anghelescu, MD|
|Principal Investigator:||Doralina Anghelescu, MD||St. Jude Children's Research Hospital|